| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Evgen Pharma says lead cancer drug candidate shows anti-cancer activity in preclinical trial
StockMarketWire.com
|
Clinical stage drug development company Evgen Pharma said preclinical data had showed its lead cancer drug candidate SFX-01 was an inhibitor of SHP2, a protein associated with a number of different cancer types.
At 8:10am: (LON:EVG) Evgen Pharma Plc share price was 0p at 8.3p
Story provided by StockMarketWire.com
|
|
|
|
|
|
